Editas Medicine, Inc. EDIT is scheduled to report third-quarter 2021 results on Nov 8, before market opens.The company’s earnings surprise history has been mixed so far, with its earnings beating estimates in two of the trailing four quarters and missing the same on the other two occasions, delivering an earnings surprise of 21.95%, on average. In the last-reported quarter, Editas reported an earnings beat of 4.71%.Shares of Editas have plunged 45% so far this year compared with the industry’s decrease of 10.2%.Image Source: Zacks Investment ResearchLet’s see how things are shaping up for the quarter to be reported.Factors at PlayWith no approved product in its portfolio at the moment, pipeline development remains the key focus for Editas. The company’s top line mainly comprises of collaboration revenues, and other research and development revenues.The company is developing its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness. In September 2021, Editas announced initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for the treatment of blindness due to LCA10.Preliminary results from the study were based on safety and efficacy data from the first two cohorts – the adult low-dose cohort and the adult mid-dose cohort. We expect management to provide more updates on the candidate’s progress at the upcoming earnings call.Please note that, last August, Editas terminated its agreement with Allergan [now part of AbbVie ABBV] and regained the full global rights to develop and commercialize its ocular medicines, including EDIT-101.Editas is evaluating the safety and efficacy of another pipeline candidate, EDIT-301, for treating sickle cell disease. The company plans to dose the first patient in the phase I/II RUBY study by the end of 2021.Editas also plans to submit an investigational new drug filing to the FDA to begin clinical studies on EDIT-301 for the treatment of beta-thalassemia by 2021-end. Investors will be keen to get more updates on the progress of this at the upcoming earnings call.The activities related to the development of EDIT-101 and other pipeline candidates are likely to have escalated operating expenses in the to-be-reported quarter.Earnings WhispersOur proven model does not conclusively predict an earnings beat for Editas this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.Earnings ESP: Editas has an Earnings ESP of -1.31% as the Most Accurate Estimate currently stands at a loss of 87 cents per share while the Zacks Consensus Estimate is pegged at a loss of 86 cents.Zacks Rank: Editas currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.Editas Medicine, Inc. Price and EPS Surprise Editas Medicine, Inc. price-eps-surprise | Editas Medicine, Inc. QuoteStocks to ConsiderHere are a few stocks you may want to consider, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle:Gemini Therapeutics, Inc. GMTX has an Earnings ESP of +17.61 % and a Zacks Rank #2, currently.Ardelyx, Inc. ARDX has an Earnings ESP of +2.22% and a Zacks Rank #3 at present. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Ardelyx, Inc. (ARDX): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Gemini Therapeutics, Inc. (GMTX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research